Leadership
Lauren Pitt – PhD
Head of Preclinical Development
- Lauren is a leader of teams in Target Identification and Validation and Preclinical Development, with almost 10 years of experience in biotechnology companies based in the US and Australia
- Received a PhD in Immunology from The University of Melbourne
- Completed post-doctoral research at the NYU School of Medicine
Gouri Betigeri
Head of Business Development
- 20 years in sales and business development from discovery through to market approval
- Extensive experience at IQVIA’s global consulting group in London for 9 years followed by 3 years in their APAC CRO in Australia
- Partnership Director in Singapore for an oncology treatment practice
- Science degree from Uni. Melbourne with post-graduate degrees in Lab. Medicine and Health and Medical Law.
Kevin Beasley
Director
Serial entrepreneur with a love for deep thinking, an uncanny perception for great opportunities, and successful in leading a range of different businesses to achieve high-performance outcomes that benefit consumers, staff and owners. Enjoys taking startups from concept to maturity.
Thomas Ulmer – FCPA, GAICD
Director
FCPA, GAICD
Commercially-minded Senior Financial Executive with 15+ years of experience directing all financial matters. Successfully implemented top- and bottom line enhancement measures across small, medium and large size businesses. Global work experience (Europe, USA and Australia) with private and listed companies as well as diverse shareholder structures (VC, PE, family-owned) across various industries (healthcare, digital health, medical devices, technology, life science, FMCG and services). Proven-track record in raising more than USD500M through NASDAQ listing, private financing rounds and various non-dilutive capital measures (partnerships, grants).
Graeme Wald – PhD
Chief Executive Officer and Director
- Graeme is an experienced Director, Chairman and CEO with a strong history in the capital markets industry
- Skilled in Financial Risk Management (Chairman of Audit & Risk Committee), Investment Funds and managing Life Science companies
- Listed five companies on the ASX while at Wilson HTM and raised approximately $750M in primary and secondary offerings
- Experience in companies developing analgesics, monoclonal antibodies, wound healing systems, cardiac assist devices, sterilization, disinfection and anaesthesia
Ben Kiefel – PhD
Co-founder, Chief Operating Officer and Director
- After graduating with a PhD in Evolutionary Biology, Ben used his entrepreneurial flare and passion for applied research and management to develop biotech businesses over the last 18 years.
- Has been at Myrio’s heart since its inception – managing its administration, HR, operations, financing and science teams
- Oversees Myrio’s Maturation Team and together with Matt, is co-inventor of ReD and numerous patents on protein display methods and compositions
Matthew Beasley
Co-founder, Chief Science Officer and Director
- Matt has been a molecular biologist for over 20 years and started his first venture in 2005
- Together with Ben, Matt is co-inventor of the ReD technology and many other patents
Board of Directors
Graeme Wald – PhD
Chief Executive Officer and Director
- Graeme is an experienced Director, Chairman and CEO with a strong history in the capital markets industry
- Skilled in Financial Risk Management (Chairman of Audit & Risk Committee), Investment Funds and managing Life Science companies
- Listed five companies on the ASX while at Wilson HTM and raised approximately $750M in primary and secondary offerings
- Experience in companies developing analgesics, monoclonal antibodies, wound healing systems, cardiac assist devices, sterilization, disinfection and anaesthesia
Ben Kiefel – PhD
Co-founder, Chief Operating Officer and Director
- After graduating with a PhD in Evolutionary Biology, Ben used his entrepreneurial flare and passion for applied research and management to develop biotech businesses over the last 18 years.
- Has been at Myrio’s heart since its inception – managing its administration, HR, operations, financing and science teams
- Oversees Myrio’s Maturation Team and together with Matt, is co-inventor of ReD and numerous patents on protein display methods and compositions
Matthew Beasley
Co-founder, Chief Science Officer and Director
- Matt has been a molecular biologist for over 20 years and started his first venture in 2005
- Together with Ben, Matt is co-inventor of the ReD technology and many other patents
Kevin Beasley
Director
Serial entrepreneur with a love for deep thinking, an uncanny perception for great opportunities, and successful in leading a range of different businesses to achieve high-performance outcomes that benefit consumers, staff and owners. Enjoys taking startups from concept to maturity.
Thomas Ulmer – FCPA, GAICD
Director
FCPA, GAICD
Commercially-minded Senior Financial Executive with 15+ years of experience directing all financial matters. Successfully implemented top- and bottom line enhancement measures across small, medium and large size businesses. Global work experience (Europe, USA and Australia) with private and listed companies as well as diverse shareholder structures (VC, PE, family-owned) across various industries (healthcare, digital health, medical devices, technology, life science, FMCG and services). Proven-track record in raising more than USD500M through NASDAQ listing, private financing rounds and various non-dilutive capital measures (partnerships, grants).
Graeme Wald - PhD
Chief Executive Officer
Ben Kiefel - PhD
Co-founder and Chief Operating Officer
Matthew Beasley
Co-founder and Chief Science Officer
Lauren Pitt - PhD
Head of Preclinical Development
Matthew Beasley
Co-founder and Chief Science Officer
Lauren Pitt - PhD
Head of Preclinical Development
Kevin Beasley
Thomas Ulmer
FCPA, GAICD
Graeme Wald
PhD
Ben Kiefel
PhD
Matt Beasley
Graeme Wald
Chief Executive Officer
Experienced Director, Chairman and CEO with a demonstrated history of working in the capital markets industry and managing Life Science companies. Skilled in Financial Risk Management (Chairman of Audit & Risk Committee), Investment Funds and managing Life Science companies. Strong professional achievements demonstrated by restructuring and re-capitalising companies. Listed five companies on the ASX while at Wilson HTM and raised approximately $750M in primary and secondary offerings.
I have worked with companies developing technologies that include analgesics, monoclonal antibodies, skin repair systems, cystic fibrosis, cardiac assist devices, sterilisation and disinfection and anaesthesia.
- Graeme joined Myrio in 2023 as Director and CEO.
Ben Kiefel
Chief Operating Officer
Ben co-founded Affinity in 2009 and serves as COO and a Director. After starting his career in Evolutionary Biology, Ben realized early that he had an entrepreneurial flare and a passion for applied research…
- Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion
- Targeting of intracellular oncoproteins with peptide-centric CARs
Matt Beasley
Chief Science Officer
Matt co-founded Affinity in 2009 and serves as CSO and a Director. Matt has been a molecular biologist for over 20 years and started his first venture in 2005. Together with Ben,…Doris Flores
Nulla mauris dolor, gravida a varius blandit, auctor eget purus. Phasellus scelerisque sapien sit amet mauris laoreet, eget scelerisque nunc cursus. Duis ultricies malesuada.
Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Orci varius.
- Mauris rhoncus orci in imperdiet placerat
- Curabitur sed iaculis dolor, non congue ligula mus
